DREAMM-7 result with ADC Blenrep in multiple myeloma

DREAMM-7 result with ADC Blenrep in multiple myeloma

The interim results just posted of the DREAMM7 head-to-head trial show that the Blenrep combination in multiple myeloma offers great promise as a potential new standard of care. In the phase III DREAMM7 study of almost 500 patients, Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BorDex) nearly tripled progression-free survival (PFS) compared with daratumumab plus BorDex as second-line treatment in relapsed or refractory multiple myeloma. Median PFS for the Blenrep combination was 36.6 months versus 13.4 months for the daratumumab combined therapy. There was also a strong overall survival trend (43% reduction in the risk of death) in favour of the Blenrep combination. Other endpoints, such as median complete response rate, minimal residual disease and duration of response, were also doubled with Blenrep therapy compared with the current standard of care. Multiple myeloma patients with disease relapse following first-line therapy now have a potentially new second-line option. The full results of this trial are eagerly awaited, but these data highlight how antibody-drug conjugates (ADCs) are a drug class worth keeping an eye on in 2024 as the ‘hot new thing’.

READ THE ARTICLE – https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/

Share this post